AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

April 13, 2018: By Jon Swedien

Applied Genetic Technologies Corporation, in collaboration with Biogen, has completed enrollment for a Phase I/II trial of its gene therapy candidate for x-linked retinoschisis (XLRS), the Massachusetts-based company announced April 10.

The open-label, dose-escalation study is designed to assess the safety and efficacy of intravitreal administration of the AAV-based gene therapy. About 27 patients diagnosed with XLRS caused by mutations in the RS1 gene will participate in the study, AGTC said.

The company said it expects topline data by Q4-2018, with the final analysis to come at the 12-month time point.

Currently, there no FDA-approved treatment options for XLRS, a leading cause of macular degeneration in young men, AGTC said.

Trial participants were enrolled sequentially in groups. Participants in one group received a low-dose, in another group participants received a middle dose, and participants in a third group received a high dose. In a fourth group, participants received the maximum tolerated dose as determined by the first three groups. In addition, a group of pediatric patients were enrolled at the middle dose.

AGTC said that although the primary endpoint of this study is designed to evaluate safety, efficacy will also be measured by an evaluation of changes in visual structure, function, and quality of life.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023